≡ Risteys
R9

Documentation Changelog GitHub Contact & Feedback

Recurring oral aphthae, including avohilmo

PheWeb

K11_APHTA_RECUR_INCLAVO

No definition available.

Endpoint definition

↥
FinnGen phenotype data

392423 individuals

diagram downward connector

Apply sex-specific rule None

392423

diagram downward connector

Check conditions None

392423

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Primary healthcare outpatient: ICD-10: K12.00, K12.01, K12.02, K12.03, K12.10, K12.11, K12.12, K12.13, K12.14, K12.18
Hospital Discharge: ICD-10 K12.00, K12.01, K12.02, K12.03, K12.10, K12.11, K12.12, K12.13, K12.14, K12.18
Cause of death: ICD-10 K12.00, K12.01, K12.02, K12.03, K12.10, K12.11, K12.12, K12.13, K12.14, K12.18

3 out of 7 registries used, show all original rules.

3756

diagram downward connector

Check minimum number of events None

3756

diagram downward connector

Include endpoints None

3756

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

3577

diagram downward connector
K11_APHTA_RECUR_INCLAVO

Control definitions

Controls for this endpoint are individuals that are not cases.

Extra metadata

First used in FinnGen datafreeze DF7

Summary Statistics

↥

Key figures

All Female Male
Number of individuals 3577 2385 1192
Unadjusted prevalence (%) 0.95 1.13 0.72
Mean age at first event (years) 55.27 53.71 58.37

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.05 3.58 [2.12, 6.04] 1.7e-6 220
15 years 0.01 1.11 [0.64, 1.93] 7.0e-1 57
5 years 0.00 3.67 [2.42, 5.58] 1.1e-9 88
1 year 0.00 13.30 [8.95, 19.77] 1.8e-37 64

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: K11_APHTA_RECUR_INCLAVO – Recurring oral aphthae, including avohilmo
GWS hits:

Survival analyses between endpoints

↥

Plot

before Recurring oral aphthae, including avohilmo
after Recurring oral aphthae, including avohilmo

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Recurring oral aphthae, including avohilmo

↥

Endpoint not on priority list, no data to show.